Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | XPO1 | O14980 | 1/20 | 0.45 |
| ▸ | JUN | P05412 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2652670 | 0.90 | P2RX1 (0.60) | P2RX1ALDH1A1MAPTFAAHTRPV1 | |
| SCHEMBL1077962 | 0.86 | TLR8 (0.50) | SLC13A3ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL3990068 | 0.85 | MAPT (0.59) | ALDH1A1POLBMAPTCYP1A2RAD51 | |
| SCHEMBL30075158 | 0.85 | P2RX1 (0.51) | P2RX1ALDH1A1MAPTFAAHTRPV1 | |
| SCHEMBL16907563 | 0.85 | P2RX1 (0.51) | P2RX1ALDH1A1MAPTFAAHTRPV1 | |
| SCHEMBL12435451 | 0.83 | SLC13A3 (0.52) | SLC13A3P2RX1POLBMAPTTRPV1 | |
| SCHEMBL1012287 | 0.83 | ALDH1A1 (0.57) | P2RX1ALDH1A1POLBMAPTFAAH | |
| SCHEMBL29739471 | 0.83 | POLB (0.48) | P2RX1ALDH1A1POLBMAPTCYP1A2 | |
| SCHEMBL23537539 | 0.82 | POLB (0.52) | ALDH1A1POLBMAPTCYP1A2RAD51 | |
| SCHEMBL16907464 | 0.82 | MAPT (0.66) | P2RX1ALDH1A1MAPTFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORP. (US) | 2018-08-21 | — | — | US | disclosed |
| EP-2268623-B9 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2017-10-19 | — | — | US | disclosed |
| US-9730937-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-15 | — | — | US | disclosed |
| EP-3147281-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORP. | 2016-07-14 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9320739-B2 | RAF kinase modulator compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| EP-2268623-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2011-01-05 | — | — | EP | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| US-7625922-B2 | Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-12-01 | — | — | US | disclosed |
| WO-2009117080-A1 | QUINAZOLINE DERIVATIVES AS RAF KINASE MODULATORS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATON (US) | 2009-09-24 | — | — | WO | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| EP-1812433-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | Cancer Research Technology Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006043090-A1 | IMIDAZO[4,5-B]PYRIDIN-2-ONE AND OXAZOLO[4,5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | BRAF, RAF1, ARAF | SLC13A3 4469/4885P2RX1 3706/4885ALDH1A1 4211/4885 |
| US-10053430-B2 | RAF kinase modulator compounds and methods of use thereof | BRAF, RAF1, ARAF | SLC13A3 4478/4885P2RX1 3151/4885ALDH1A1 2803/4885 |
| US-20160199375-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | SLC13A3 4478/4885P2RX1 3151/4885ALDH1A1 2803/4885 |
| US-20170298029-A1 | RAF KINASE MODULATOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | SLC13A3 4478/4885P2RX1 3151/4885ALDH1A1 2803/4885 |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | SLC13A3 2399/4885P2RX1 2239/4885ALDH1A1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.